Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, Prenner S, Zamani P, Seiffert DA, Car BD, Gordon DA, Margulies K, Cappola T, Chirinos JA. Cohen JB, et al. Among authors: car bd. JACC Heart Fail. 2020 Mar;8(3):172-184. doi: 10.1016/j.jchf.2019.09.009. Epub 2020 Jan 8. JACC Heart Fail. 2020. PMID: 31926856 Free PMC article. Clinical Trial.
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction.
Chirinos JA, Orlenko A, Zhao L, Basso MD, Cvijic ME, Li Z, Spires TE, Yarde M, Wang Z, Seiffert DA, Prenner S, Zamani P, Bhattacharya P, Kumar A, Margulies KB, Car BD, Gordon DA, Moore JH, Cappola TP. Chirinos JA, et al. Among authors: car bd. J Am Coll Cardiol. 2020 Mar 24;75(11):1281-1295. doi: 10.1016/j.jacc.2019.12.069. J Am Coll Cardiol. 2020. PMID: 32192654 Free PMC article.
Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection Fraction.
Selvaraj S, Kim J, Ansari BA, Zhao L, Cvijic ME, Fronheiser M, Mohan-Rao Vanjarapu J, Kumar AA, Suri A, Yenigalla S, Satija V, Ans AH, Narvaez-Guerra O, Herrera-Enriquez K, Obeid MJ, Lee JJ, Jehangir Q, Seiffert DA, Car BD, Gordon DA, Chirinos JA. Selvaraj S, et al. Among authors: car bd. JACC Cardiovasc Imaging. 2021 Jan;14(1):203-215. doi: 10.1016/j.jcmg.2020.07.022. Epub 2020 Sep 16. JACC Cardiovasc Imaging. 2021. PMID: 32950445 Free PMC article.
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.
Chirinos JA, Zhao L, Jia Y, Frej C, Adamo L, Mann D, Shewale SV, Millar JS, Rader DJ, French B, Brandimarto J, Margulies KB, Parks JS, Wang Z, Seiffert DA, Fang J, Sweitzer N, Chistoffersen C, Dahlbäck B, Car BD, Gordon DA, Cappola TP, Javaheri A. Chirinos JA, et al. Among authors: car bd. Circulation. 2020 May 5;141(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.045323. Epub 2020 Apr 2. Circulation. 2020. PMID: 32237898 Free PMC article.
Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Achanzar WE, Moyer CF, Marthaler LT, Gullo R, Chen SJ, French MH, Watson LM, Rhodes JW, Kozlosky JC, White MR, Foster WR, Burgun JJ, Car BD, Cosma GN, Dominick MA. Achanzar WE, et al. Among authors: car bd. Toxicol Appl Pharmacol. 2007 Sep 15;223(3):246-56. doi: 10.1016/j.taap.2007.06.015. Epub 2007 Jul 3. Toxicol Appl Pharmacol. 2007. PMID: 17663016
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699.
Yang Z, Wang H, Salcedo TW, Suchard SJ, Xie JH, Schneeweis LA, Fleener CA, Calore JD, Shi R, Zhang SX, Rodrigues AD, Car BD, Marathe PH, Nadler SG. Yang Z, et al. Among authors: car bd. J Pharmacol Exp Ther. 2015 Dec;355(3):506-15. doi: 10.1124/jpet.115.227249. Epub 2015 Oct 6. J Pharmacol Exp Ther. 2015. PMID: 26442523
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat.
Fielden MR, Nie A, McMillian M, Elangbam CS, Trela BA, Yang Y, Dunn RT 2nd, Dragan Y, Fransson-Stehen R, Bogdanffy M, Adams SP, Foster WR, Chen SJ, Rossi P, Kasper P, Jacobson-Kram D, Tatsuoka KS, Wier PJ, Gollub J, Halbert DN, Roter A, Young JK, Sina JF, Marlowe J, Martus HJ, Aubrecht J, Olaharski AJ, Roome N, Nioi P, Pardo I, Snyder R, Perry R, Lord P, Mattes W, Car BD; Predictive Safety Testing Consortium; Carcinogenicity Working Group. Fielden MR, et al. Among authors: car bd. Toxicol Sci. 2008 May;103(1):28-34. doi: 10.1093/toxsci/kfn022. Epub 2008 Feb 14. Toxicol Sci. 2008. PMID: 18281259
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
Albright CF, Graciani N, Han W, Yue E, Stein R, Lai Z, Diamond M, Dowling R, Grimminger L, Zhang SY, Behrens D, Musselman A, Bruckner R, Zhang M, Jiang X, Hu D, Higley A, Dimeo S, Rafalski M, Mandlekar S, Car B, Yeleswaram S, Stern A, Copeland RA, Combs A, Seitz SP, Trainor GL, Taub R, Huang P, Oliff A. Albright CF, et al. Mol Cancer Ther. 2005 May;4(5):751-60. doi: 10.1158/1535-7163.MCT-05-0006. Mol Cancer Ther. 2005. PMID: 15897239
53 results